First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference25 articles.
1. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma.;Motzer;J Clin Oncol,2002
2. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.;Motzer;N Engl J Med,2007
3. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.;Motzer;J Clin Oncol,2009
4. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival.;Escudier;J Clin Oncol,2010
5. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.;Rini;J Clin Oncol,2010
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database;Clinical Genitourinary Cancer;2023-02
2. Decrease of Pro-Angiogenic Monocytes Predicts Clinical Response to Anti-Angiogenic Treatment in Patients with Metastatic Renal Cell Carcinoma;Cells;2021-12-22
3. Skeletal Muscle Loss during Multikinase Inhibitors Therapy: Molecular Pathways, Clinical Implications, and Nutritional Challenges;Nutrients;2020-10-12
4. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values;Cancer Treatment and Research Communications;2020
5. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer;Cancer Chemotherapy and Pharmacology;2019-01-24
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3